MedTrace Logo

Liposomal Bupivacaine in Adductor Canal Blocks (ACB)

NCT04539730 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2021-12-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether liposomal bupivacaine is superior to normal bupivacaine in terms of providing better pain control postoperatively after total knee arthroplasty.

Conditions

  • Arthroplasty Complications
  • Adductor Canal Block
  • Peripheral Nerve Block
  • Opioid Use

Interventions

DRUG

Liposomal bupivacaine

266 mg or 20 ml Liposomal Bupivacaine injectable solution

PROCEDURE

Drug: SoC Ropivacaine

0.5% (5mg/mL) 20 mL single dose SOC anesthetic Ropivacaine.

Sponsors & Collaborators

  • University of Miami

    lead OTHER

Principal Investigators

  • Jaime Carvajal, MD · University of Miami

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2022-12-01
Completion
2022-12-01
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04539730 on ClinicalTrials.gov